Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13573065 | 1.00 | ALDH1A1 (0.50) | ALDH1A1LMNATSHRHSD17B10TDP1 | |
| SCHEMBL13773133 | 1.00 | ALDH1A1 (0.50) | ALDH1A1LMNATSHRHSD17B10TDP1 | |
| SCHEMBL13773120 | 1.00 | ALDH1A1 (0.50) | ALDH1A1LMNATSHRHSD17B10TDP1 | |
| SCHEMBL9463612 | 0.95 | ALDH1A1 (0.46) | ALDH1A1LMNATSHRHSD17B10TDP1 | |
| SCHEMBL10267375 | 0.95 | ALDH1A1 (0.46) | ALDH1A1LMNATSHRHSD17B10TDP1 | |
| SCHEMBL13176815 | 0.95 | ALDH1A1 (0.46) | ALDH1A1LMNATSHRHSD17B10TDP1 | |
| SCHEMBL4561852 | 0.95 | ALDH1A1 (0.46) | ALDH1A1LMNATSHRHSD17B10TDP1 | |
| SCHEMBL21031 | 0.89 | — | — | |
| SCHEMBL23071516 | 0.87 | ALDH1A1 (0.39) | ALDH1A1LMNATSHRHSD17B10 | |
| SCHEMBL14944912 | 0.87 | ALDH1A1 (0.39) | ALDH1A1LMNATSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 351 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3604316-B1 | SYNTHESIS OF BORONATE SALTS | MELINTA THERAPEUTICS INC (US) | 2023-12-06 | — | — | EP | claimed |
| US-10669292-B2 | Synthesis of boronate salts and uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2020-06-02 | — | — | US | claimed |
| EP-3604316-A1 | SYNTHESIS OF BORONATE SALTS | Rempex Pharmaceuticals, Inc. (US) | 2020-02-05 | — | — | EP | claimed |
| US-20200031851-A1 | SYNTHESIS OF BORONATE SALTS AND USES THEREOF | MELINTA SUBSIDIARY CORP. | 2020-01-30 | — | — | US | claimed |
| EP-1660507-B2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | MILLENNIUM PHARM INC (US) | 2017-01-04 | — | — | EP | claimed |
| EP-2463374-A2 | Isolated alcohol dehydrogenase enzymes and uses thereof | Bio Architecture Lab, Inc. (US) | 2012-06-13 | — | — | EP | claimed |
| EP-2195440-A2 | BIOFUEL PRODUCTION | Bio Architecture Lab, Inc. (US) | 2010-06-16 | — | — | EP | claimed |
| EP-1660507-B9 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-03-24 | — | — | EP | claimed |
| EP-1660507-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2009-08-05 | — | — | EP | claimed |
| US-20090155873-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-18 | — | — | US | claimed |
| EP-1206449-A1 | LACTAM INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-05-22 | — | — | EP | claimed |
| WO-2001064678-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-07 | — | — | WO | claimed |
| WO-2001007407-A1 | LACTAM INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-02-01 | — | — | WO | claimed |
| US-5736535-A | 1-pyrimidinylacetamide compounds which are inhibitors of human leukocyte elastase | ZENECA LIMITED (GB) | 1998-04-07 | — | — | US | claimed |
| EP-0636143-B1 | ALPHA-AMINOBORONIC ACID PEPTIDES AND THEIR USE AS ELASTASE INHIBITORS | ZENECA LTD (GB) | 1997-09-24 | — | — | EP | claimed |
| US-5639739-A | USEFUL FOR TREATING THROMBOSIS IN MAMMALS BY INHIBITING TRYPSIN-LIKE SERINE PROTEASE ENZYMES | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-06-17 | — | — | US | claimed |
| EP-0636144-A1 | ALPHA-AMINOBORONIC ACID PEPTIDES AND THEIR USE AS ELASTASE INHIBITORS | ZENECA LIMITED (GB) | 1995-02-01 | — | — | EP | claimed |
| EP-0636143-A1 | ALPHA-AMINOBORONIC ACID PEPTIDES AND THEIR USE AS ELASTASE INHIBITORS. | ZENECA LTD (GB) | 1995-02-01 | — | — | EP | claimed |
| WO-1993021213-A1 | ALPHA-AMINOBORONIC ACID PEPTIDES AND THEIR USE AS ELASTASE INHIBITORS | ZENECA LIMITED (GB) | 1993-10-28 | — | — | WO | claimed |
| WO-1993021214-A1 | ALPHA-AMINOBORONIC ACID PEPTIDES AND THEIR USE AS ELASTASE INHIBITORS | ZENECA LIMITED (GB) | 1993-10-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031851-A1 | SYNTHESIS OF BORONATE SALTS AND USES THEREOF | BTD, BCL6B, BRI3BP | ALDH1A1 3175/4885LMNA 2796/4885TSHR 3061/4885 |
| US-10669292-B2 | Synthesis of boronate salts and uses thereof | BTD, BCL6B, BRI3BP | ALDH1A1 3175/4885LMNA 2796/4885TSHR 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.